Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine

JCM, Free Full-Text

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study - Aikaterini Detoraki, Eugenio Tremante, Maria D'Amato, Cecilia Calabrese, Claudia

Hobson ENT - I am exceedingly proud to have been involved in this multicentre, phase 3 RCT on Mepolizumab which is a new class of biological agent used of the treatment of

Mepolizumab as Anti-interleukin-5 Therapy for Chronic Rhinosinusitis with Nasal Polyposis - touchRESPIRATORY

Biomedicines, Free Full-Text

Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps

Study Designs NUCALA (mepolizumab) for HCPs

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Biomedicines, Free Full-Text

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up - Desrosiers - International Forum of Allergy & Rhinology - Wiley Online Library

FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps - PharmaLive

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count - ScienceDirect

Eosinophils & MOA NUCALA (mepolizumab) for CRSwNP

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count - ScienceDirect